Celemics Valuation

Is A331920 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A331920 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A331920's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A331920's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A331920?

Key metric: As A331920 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A331920. This is calculated by dividing A331920's market cap by their current earnings.
What is A331920's PE Ratio?
PE Ratio	2.4x
Earnings	₩11.01b
Market Cap	₩26.94b

A331920 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.9x
Enterprise Value/EBITDA	-5.9x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A331920's PE Ratio compare to its peers?

The above table shows the PE ratio for A331920 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	15.5x
A215380 WOOJUNG BIO	23.8x	n/a	₩28.2b
A238120 Aligned Genetics	14.3x	n/a	₩47.3b
A359090 C&R Research	12.5x	n/a	₩64.4b
A347740 P&K Skin Research Center	11.6x	n/a	₩62.0b
A331920 Celemics	2.4x	n/a	₩26.9b

Price-To-Earnings vs Peers: A331920 is good value based on its Price-To-Earnings Ratio (2.4x) compared to the peer average (15.5x).

Price to Earnings Ratio vs Industry

How does A331920's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	31.9x	26.8%
A331920 Celemics	2.4x	n/a	US$19.18m

1 Company		Estimated Growth	Market Cap
Industry Avg.	31.9x	26.8%
A331920 Celemics	2.4x	n/a	US$19.18m

No more companies

Price-To-Earnings vs Industry: A331920 is good value based on its Price-To-Earnings Ratio (2.4x) compared to the Asian Life Sciences industry average (31.9x).

Price to Earnings Ratio vs Fair Ratio

What is A331920's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A331920 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	2.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A331920's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bioneer

₩513.9b

Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.

A064550

₩19,910.00

-0.7%

-34.6%

Medy-Tox

₩867.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩128,800.00

2.1%

-41.2%

J2KBIO

₩52.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,180.00

-4.8%

n/a